School of Medicine, Department of Medicine, Queen's University, Kingston, ON, Canada.
Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Arch Dermatol Res. 2024 Aug 19;316(8):539. doi: 10.1007/s00403-024-03332-2.
Treatment of pyoderma gangrenosum (PG) is challenging due to the absence of standardized guidelines and the lack of evidence-based, effective treatment options. Here, we performed a systematic review to summarize the use of biologics and their efficacy in the treatment of PG. We searched PubMed/MEDLINE, EMBASE, and Cochrane electronic databases from their inception to September 22nd, 2022, and included 82 peer-reviewed studies with a total of 108 patients. Infliximab, adalimumab, and etanercept were the most utilized biologic therapies in the treatment of PG in 64.8% (70/108), 16.7% (18/108), and 11.1% (12/108) of the cases, respectively. With respect to treatment response, 88.9% (96/108) of the patients achieved complete resolution of PG with biologic therapies. The average number of days to improvement and resolution of PG treated after starting biologic therapies was 30 and 161, respectively. PG recurred in 15.5% (11/71) of those reported the outcome. Our study suggests that biologic therapies may be an attractive therapeutic option for PG with an excellent efficacy.
由于缺乏标准化指南以及缺乏基于证据的有效治疗选择，治疗坏疽性脓皮病 (PG) 具有挑战性。在这里，我们进行了系统评价，以总结生物制剂的应用及其在 PG 治疗中的疗效。我们搜索了 PubMed/MEDLINE、EMBASE 和 Cochrane 电子数据库，从建库到 2022 年 9 月 22 日，共纳入了 82 项同行评议的研究，共有 108 例患者。英夫利昔单抗、阿达木单抗和依那西普是治疗 PG 中使用最多的生物治疗药物，分别占 64.8%（70/108）、16.7%（18/108）和 11.1%（12/108）。关于治疗反应，96%（96/108）的患者使用生物制剂治疗后 PG 完全缓解。开始生物治疗后改善和 PG 缓解的平均天数分别为 30 天和 161 天。报告结局的患者中有 15.5%（11/71）PG 复发。我们的研究表明，生物制剂治疗 PG 可能是一种有吸引力的治疗选择，疗效极佳。
